Alterity Therapeutics (ATHE) Common Equity (2009 - 2025)

Alterity Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $35.6 million for Q4 2025.

• On a quarterly basis, Common Equity rose 599.79% year-over-year to $35.6 million in Q4 2025; TTM through Dec 2025 was $35.6 million, a 599.79% increase from a year earlier, with the FY2025 full-year figure at $27.2 million, up 198.64% from the prior year.
• Common Equity advanced to $35.6 million in Q4 2025 per ATHE's latest filing, from $27.2 million in the prior quarter.
• Across five years, Common Equity topped out at $35.6 million in Q4 2025 and bottomed at $228129.1 in Q2 2023.
• The 5-year median for Common Equity is $21.0 million (2021), against an average of $19.0 million.
• Across the five-year window, Common Equity tumbled 99.1% in 2023 and surged 5560.24% in 2024, its largest moves.
• Year by year, Common Equity stood at $30.0 million in 2021, then tumbled by 38.37% to $18.5 million in 2022, then plunged by 37.87% to $11.5 million in 2023, then tumbled by 55.62% to $5.1 million in 2024, then jumped by 599.79% to $35.6 million in 2025.
• Per Business Quant, the three latest ATHE Common Equity figures stand at $35.6 million (Q4 2025), $27.2 million (Q2 2025), and $5.1 million (Q4 2024).